Outcomes of treatment of severe COVID-19 pneumonia with tocilizumab: a report of two cases from Tunisia.
Pan Afr Med J
; 40: 126, 2021.
Article
in English
| MEDLINE | ID: covidwho-1591427
ABSTRACT
The SARS CoV-2 pandemic is a global health threat with high morbidity and mortality (1 to 4%) rates. COVID-19 is correlated with important immune disorders, including a "cytokine storm". A new therapeutic approach using the immunomodulatory drug, Anti-IL6 (tocilizimub), has been proposed to regulate it. We report here the first Tunisian experience using tocilizimub in two severe cases of COVID-19 pneumonia. The diagnosis was confirmed by chest scan tomography. Biological parameters showed a high level of Interleukin-6 (IL-6) that increased significantly during hospitalization. The patients developed hypoxia, so they received intravenously 8 mg/kg body weight tocilizumab. There was a resultant decrease in the level of IL6, with clinically good evolution. Blocking the cytokine IL-6 axis is a promising therapy for patients developing COVID-19 pathology.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19 Drug Treatment
Type of study:
Case report
/
Prognostic study
Limits:
Humans
Country/Region as subject:
Africa
Language:
English
Journal:
Pan Afr Med J
Year:
2021
Document Type:
Article
Affiliation country:
Pamj.2021.40.126.28020
Similar
MEDLINE
...
LILACS
LIS